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tion can be considered to be a very cost-effective strategy
when used to prevent progression of AMD.
PES8
LOW VISUAL ACUITY AND BLINDNESS SOCIAL
COSTS IN FRANCE
Lafuma A1, Pradet S1, Berdeaux G2
1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison,
France
OBJECTIVES: To estimate disability pension costs and
institutionalisation associated with low visual acuity
(LVA) and blindness in France. METHODS: Two
national surveys performed by INSEE (Institut National
de la Statistique et des Etudes Economiques) on disabil-
ity and institutionalisation in France (1998–1999) were
carried out. Information (socio-demographics, disability
reasons, disability pension and type of institution) was
collected on two national representative samples of living
at home and institutionalised populations. Three groups
were identiﬁed in each case: blind people, LVA people and
a control group (non-blind/LVA general population).
Linear regression was used to adjust the group pension
differences for gender, age and professional categories.
The probability of being institutionalised due to blind-
ness/LVA when >55 was estimated with Bayesian rules.
RESULTS: 15,288 people were included in the survey of
institutionalised persons; 279 were blind and 2,536 had
LVA. The control group included more women. The blind
were younger while those with LVA were older; the blind
had fewer jobs. 16,915 people were included in the living
at home survey; 86 were blind and 1,080 had LVA. The
control group had more women and was younger, while
those with LVA had less skilled jobs. Disability pensions
varied with gender, age and professional categories. Insti-
tutionalised blind people received €112.64 per month
more than the control group and €484.33 more than
people living at home. Figures for LVA patients were
respectively €19.22 and €201.52. Probability of being
institutionalised was 6.13% for blind people, 5.91% for
LVA and 1.14% for the control group. A person has a 5.4
times greater chance of being institutionalised if blind and
5.2 times with LVA. CONCLUSION: Blindness and LVA
lead to additional disability pensions payments and insti-
tutionalisation. Medical programs aimed at delaying
blindness or LVA may have economic consequences
outside the direct medical costs that should be taken into
account.
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COST-EFFECTIVENESS AND COST-UTILITY OF
OLOPATADINE IN THE TREATMENT OF
SEASONAL ALLERGIC CONJUNCTIVITIS (SAC)
IN 6 EUROPEAN COUNTRIES
Lilliu H1, Smith AF2, Le Pen C1, Maurel F1
1Clp-santé, Paris, France; 2Alcon Laboratories Ltd and Nufﬁeld
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OBJECTIVES: To assess cost-effectiveness and cost-
utility ratios of a new anti-allergic agent Olopatadine in
comparison to the reference treatment, Levocabastine, 
in Seasonal Allergic Conjunctivitis (SAC) in France,
Germany, Italy, Spain, Sweden and the United Kingdom.
METHODS: Data from a randomized, double-blind clin-
ical trial of Olopatadine (O) versus Levocabastine (L) in
SAC were used in the analysis. A total of 210 patients
were randomized (O:101, L:109). Ocular symptoms 
and investigator’s Clinical Global Impression (CGI) were
reported at baseline and at days 7, 14, 30 and 42. Fac-
torial analysis techniques were used to derive a synthetic
symptoms score (effectiveness score) from multi-
dimensional symptom scales. In order to transform symp-
toms scores into utility scores, a panel of 32 ophthal-
mologists was interviewed in the 6 European countries to
collect data on the painfulness of various symptomatic
statuses. Curves representing the evolution of effective-
ness and utility scores over time were projected from 42
to 90 days, assuming 3 types of treatment effects after day
42, namely, a maintained effect (H1), a catch-up on com-
paritor (H2) and no additional effect (H3). Areas under
effectiveness and utility curves (AUCs) were computed in
both arms. Olopatadine-Levocabastine differentials were
respectively represented in the effectiveness criterion as
the number of Symptoms Adjusted Days saved, (SAD)
and in the utility criterion as the number of Quality
Adjusted Days saved, (QAD). RESULTS: Olopatadine
showed a gain from 1.3 (H3) to 2.3 (H1) SADs, and from
0.8 (H3, UK) to 4.2 (H1, Germany) QADs, over 3
months. Assuming a 20% higher price for Olopatadine
compared to Levocabastine, the incremental cost-
effectiveness ratios of Olopatadine ranged from €1.27
(H1, France) to €21.3 (H3, Italy) per SAD saved, while
incremental cost-utility ratio ranged from €1.06 to €23.4
per QAD saved. CONCLUSION: Olopatadine showed
reasonable cost-effectiveness and cost-utility ratios versus
Levocabastine in the treatment of SAC for 6 European
countries.
PES10
PHARMACOECONOMIC EVALUATION OF A
NEW TWO COMPOUND OINTMENT
(DAIVOBET®) AND CALCIPOTRIOL
(DAIVONEX®) IN THE TREATMENT OF
PSORIASIS VULGARIS IN SWEDEN
Sørensen M, Nørregaard J
LEO Pharma, Ballerup, Denmark
OBJECTIVES: The objective of the study is to investigate
the cost-effectiveness of treating patients with psoriasis
vulgaris in Sweden. METHODS: The cost-effectiveness
analysis was performed by comparing effectiveness data
obtained from an international multicentre study with the
cost of the two products. RESULTS: The expected cost
per percentage reduction in PASI in Sweden is SEK 15.78
for TCP twice daily, followed by SEK 8.98 for cal-
cipotriol, and TCP once daily SEK 8.29 when comparing
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four weeks of treatment. Thus, TCP once daily is the most
cost-effective treatment regime. In addition, when com-
paring current treatment practice (twice daily calcipotriol
applied for 8 weeks) to the once daily application of the
TCP for 4 weeks, it will reduce the treatment cost for pso-
riasis in Sweden by 46.2%. CONCLUSION: This study
demonstrates that TCP applied once daily is both cost-
effective and a cost-minimising treatment strategy, which
offers psoriasis patients a convenient and highly effective
treatment regime with a rapid onset of action.
PES11
ECONOMIC EVALUATION OF METHOTREXATE
AND CYCLOSPORIN A FOR PATIENTS WITH
SEVERE PSORIASIS
Opmeer B, Heydendael V, deBorgie C, Spuls P, Bossuyt P,
deRie M, Bos J
Academic Medical Center/University of Amsterdam,
Amsterdam, Netherlands
Despite longstanding use of Methotrexate (MTX) and
Cyclosporin A (CsA) in patients with severe psoriasis,
true comparative evidence derived from a RCT evaluat-
ing these systemic therapies was still lacking. Our
prospective, double blinded randomised comparison of
16 weeks treatment with MTX or CsA in 85 patients
showed comparable effectiveness and quality of life 
(Heydendael, submitted). The question arises, whether
other aspects, including costs of treatment of psoriasis,
side effects of subjective perspectives could be deciding
factors in treatment decision making; especially consider-
ing the different retail prices for MTX and CsA. OBJEC-
TIVES: To document the process of treatment of psoriasis
with MTX or CsA and follow-up in terms of resource
utilisation and associated costs. METHODS: Additional
data on direct medical and nonmedical costs and indirect
costs were collected for all 85 randomised patients up 
to 1 year after randomisation, and a cost minimisation
analysis was set up according to a societal perspective.
RESULTS: The average cumulative costs associated with
16 weeks treatment was €1,593 in MTX and €2,113 in
CsA (€520 difference favouring MTX), whereas 36 weeks
of follow up generated €2,417 (MTX) and €2,306 (CsA)
(difference: €111 in favour of CsA). Overall costs after
one year lead to an overall difference of €409 in favour
of MTX on a total cost of €4010 (10%). CONCLU-
SIONS: Economic arguments are not a deciding factor in
decision making between MTX or CsA for treatment of
severe psoriasis, as differences are small and costs associ-
ated with treatment and follow up management are gen-
erated by a variety of resources utilised, than costs of
systemic therapy alone.
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OBJECTIVES: The purpose of the evaluation is to show
the resource utilization and related costs per year as well
as per ﬂare for patients suffering from atopic dermatitis
in Switzerland from patients’ and third-party payers’ per-
spective. METHODS: Multi-center, retrospective cost-of-
illness study. Information as demographic characteristics,
number of ﬂares per year, consultations, hospitalizations,
cures and out-of-pocket expenditures as for e.g. OTC-
medication was collected with a patient-questionnaire.
Resource utilization of outpatient care was gained from
patient’s records. Direct and indirect costs were consid-
ered. RESULTS: Three ofﬁce-based pediatricians, two
ofﬁce-based dermatologists and two dermatology hospi-
tals participated. Sixty-ﬁve patients are included in this
study until now. Thirty-four patients sent back the ques-
tionnaire (52%). Mean age of patients is 17 years (1–70
years); about 42% are female. About 34% of the patients
have a mild course of disease; about 36% suffer from 
a moderate and 30% from a severe or extreme severe
course of disease. On average, 4.0 (SD 3.7) ﬂares per year
were reported by the patients. Two out of 31 patients
(6.5%) require hospitalization due atopic dermatitis per
year. From the patients’ perspective the main cost drivers
are OTC-medication and skin care products with annual
costs of CHF 360 per patient. Patients’ expenses for
special investigations and other devices for e.g. special
clothes and nutrition are about CHF 355 per patient. 
For additional treatment (e.g. psychotherapeutics and/or
naturopathy) patients spent about CHF 85 per year.
CONCLUSION: These preliminary results show that out-
of-pocket expenses per patient and year amount about
CHF 800. The study is still ongoing and ﬁnal cost data
from the third party payers’ perspective are under evalu-
ation until August 2002.
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RESOURCE UTILIZATION IN PATIENTS
SUFFERING FROM ATOPIC DERMATITIS IN
GERMANY
Ehlken B1, Kugland B1, Schramm B1, Quednau K2,
van Assche D3, Berger K1
1MERG—Medical Economics Research Group, Munich,
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OBJECTIVES: To estimate the resource utilization and
related costs per ﬂare and per year for patients suffering
from atopic dermatitis in Germany from patients’ and 
the third-party payers’ perspective. METHODS: Multi-
